| Added by | celine.gongora |
|---|---|
| Group name | EquipeCG |
| Item Type | Journal Article |
| Title | A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours |
| Creator | Eskens et al. |
| Author | F. a. L. M. Eskens |
| Author | P. Tresca |
| Author | D. Tosi |
| Author | L. Van Doorn |
| Author | H. Fontaine |
| Author | A. Van der Gaast |
| Author | C. Veyrat-Follet |
| Author | C. Oprea |
| Author | M. Hospitel |
| Author | V. Dieras |
| Abstract | BACKGROUND: The vascular disrupting agent ombrabulin shows synergy with docetaxel in vivo. Recommended phase II doses were determined in a dose escalation study in advanced solid tumours. METHODS: Ombrabulin (30-min infusion, day 1) followed by docetaxel (1-h infusion, day 2) every 3 weeks was explored. Ombrabulin was escalated from 11.5 to 42?mg?m(-2) with 75?mg?m(-2) docetaxel, then from 30 to 35?mg?m(-2) with 100?mg?m(-2) docetaxel. Recommended phase II dose cohorts were expanded. RESULTS: Fifty-eight patients were treated. Recommended phase II doses were 35?mg?m(-2) ombrabulin with 75?mg?m(-2) docetaxel (35/75?mg?m(-2); 13 patients) and 30?mg?m(-2) ombrabulin with 100?mg?m(-2) docetaxel (30/100?mg?m(-2); 16 patients). Dose-limiting toxicities were grade 3 fatigue (two patients; 42/75, 35/100), grade 3 neutropaenic infection (25/75), grade 3 headache (42/75), grade 4 febrile neutropaenia (30/100), and grade 3 thrombosis (35/100). Toxicities were consistent with each agent; mild nausea/vomiting, asthaenia/fatigue, alopecia, and anaemia were common, as were neutropaenia and leukopaenia. Diarrhoea, nail disorders and neurological symptoms were frequent at 100?mg?m(-2) docetaxel. Pharmacokinetic analyses did not show any relevant drug interactions. Ten patients had partial responses (seven at 30?mg?m(-2) ombrabulin), eight lasting >3 months. CONCLUSIONS: Sequential administration of ombrabulin with 75 or 100?mg?m(-2) docetaxel every 3 weeks is feasible. |
| Publication | British Journal of Cancer |
| Volume | 110 |
| Issue | 9 |
| Pages | 2170-2177 |
| Date | Apr 29, 2014 |
| Journal Abbr | Br. J. Cancer |
| Language | eng |
| DOI | 10.1038/bjc.2014.137 |
| ISSN | 1532-1827 |
| Library Catalog | PubMed |
| Extra | PMID: 24714750 PMCID: PMC4007230 |
| Tags | Adolescent, Adult, Aged, Angiogenesis Inhibitors, Antineoplastic Combined Chemotherapy Protocols, clinic, Docetaxel, Drug Interactions, Female, Humans, Male, Middle Aged, Neoplasms, sanofi, Serine, Taxoids, Treatment Outcome, Young Adult |
| Date Added | 2019/05/14 - 12:27:20 |
| Date Modified | 2019/10/24 - 15:57:21 |
| Notes and Attachments | PubMed entry (Attachment) Texte intégral (Attachment) |
Institut de Recherche en Cancérologie de
